An interventional study of Coenzyme Q10 gel and Topical curcumin gel in Oral Leukoplakia, sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Alexandria University · Not applicable, Interventional, and Treatment
Oral leukoplakia (OL) is recognized as the most common potentially malignant disorder of the oral mucosa. The pathogenesis of OL is complex and multifactorial, with oxidative stress playing a central role. Topical antioxidants have gained attention as therapeutic options to help stabilize lesions and potentially prevent malignant transformation. Both CoQ10 and curcumin have demonstrated a clinical success as strong antioxidants showing their capacity to reduce the lesion size and to stabilize the disease, ultimately preventing progression into oral malignancy. Aim: This study aims to clinically and biochemically assess the effectiveness of topical Coenzyme Q10 and Curcumin in the management of homogeneous oral leukoplakia.
42 studies on the registry are indexed under Leukoplakia, Oral; 10 are open to participants now.
This study's planned enrollment of 34 is close to the median of 35 across 22 interventional studies indexed under Leukoplakia, Oral.
Browse Leukoplakia, Oral studies →Alexandria University is the lead sponsor of 569 studies on the registry; 125 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Coenzyme Q10 gel
Other: Topical curcumin gel
Application will be performed 2-3 times daily for 4 weeks.
Application will be performed 2-3 times daily for 4 weeks.
Change in lesion size
measured clinically with a periodontal probe and/or digital images
Time frame: baseline, 4 weeks, and 12 weeks
Change in salivary markers
Unstimulated whole saliva will be collected to assess salivary oxidative stress
Time frame: baseline, 4 weeks, and 12 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alexandria University